Target HbA1c for type 2 diabetes in elderly patients cannot be set using a one-size-fits-all approach. Unlike younger adults, older people living with frailty, cognitive impairment, or significant comorbidities face a fundamentally different risk-benefit balance when it comes to glucose lowering. Tight glycaemic control that reduces complications in a 50-year-old may cause serious harm — including falls, cardiac events, and hospitalisation — in a frail 80-year-old. This article explains how UK guidance, including NICE NG28, approaches individualised HbA1c targets for older adults, and what factors should inform clinical decision-making.

Why HbA1c Targets Differ for Older Adults with Type 2 Diabetes

HbA1c targets differ for older adults because frailty, comorbidities, and reduced life expectancy shift the risk-benefit balance away from intensive control, with hypoglycaemia posing greater harm than in younger patients.

HbA1c — glycated haemoglobin — reflects average blood glucose levels over the preceding two to three months and remains the cornerstone of long-term glycaemic monitoring in type 2 diabetes. However, the same numerical target is not appropriate for every patient, and this is particularly true for older adults. Frailty, comorbidities, and social circumstances fundamentally alter the risk-benefit balance of intensive glucose lowering, often more so than chronological age alone.

In younger adults with type 2 diabetes, tighter glycaemic control is associated with meaningful reductions in microvascular complications such as retinopathy, nephropathy, and neuropathy. These benefits accrue over many years, meaning a patient in their forties or fifties has sufficient life expectancy to realise them. In contrast, an older adult — particularly one living with frailty or significant comorbidities — may not live long enough to benefit from the same degree of control, while facing a considerably higher risk of harm from over-treatment.

Older adults are more vulnerable to hypoglycaemia, which can trigger falls, fractures, cardiac arrhythmias, and acute confusion. Their ability to recognise and respond to hypoglycaemic symptoms is often diminished, and physiological recovery is slower. For these reasons, NICE guideline NG28 explicitly recommends that HbA1c targets for older adults should be individualised rather than applied uniformly, balancing the prevention of long-term complications against the real risks of over-treatment.

It is also important to note that HbA1c may be unreliable in certain conditions common in older adults, including anaemia, chronic kidney disease (CKD), haemoglobinopathies, and following a recent blood transfusion. In these situations, capillary blood glucose monitoring or continuous glucose monitoring (CGM) data may provide a more accurate picture of glycaemic control.

NICE and NHS Guidance on HbA1c Goals in Older Adults

NICE NG28 recommends 48–53 mmol/mol for most adults, but supports relaxed targets of 58–64 mmol/mol for frail older adults, guided by individual clinical circumstances and shared decision-making.

NICE guideline NG28 (Type 2 Diabetes in Adults: Management, updated 2022) provides the primary framework for HbA1c targets in the UK. For most adults with type 2 diabetes managed with lifestyle measures or a single non-hypoglycaemic drug such as metformin, NICE recommends a target HbA1c of 48 mmol/mol (6.5%). For those on drugs that carry a risk of hypoglycaemia — such as sulphonylureas or insulin — the recommended target rises to 53 mmol/mol (7.0%) to provide a safety margin.

NICE also advises that treatment should generally be intensified when HbA1c rises to 58 mmol/mol (7.5%) or above, provided this is appropriate for the individual. Conversely, if a patient's HbA1c is unexpectedly low — particularly if they are taking a sulphonylurea or insulin — or if hypoglycaemic episodes are occurring, this should prompt a clinical review and consideration of de-intensification, in line with NICE NG28 principles.

For older adults with frailty, significant comorbidities, or limited life expectancy, NICE and NHS guidance explicitly acknowledges that standard targets may not be appropriate and should be relaxed. UK expert consensus — including guidance from the Joint British Diabetes Societies (JBDS) and the Primary Care Diabetes Society (PCDS) — suggests that a less stringent HbA1c in the region of 58–64 mmol/mol (7.5–8.0%) may be reasonable for frail older adults, though this is not a fixed NICE recommendation and should be treated as a clinical judgement informed by individual circumstances.

The goal is to avoid both the harms of hyperglycaemia — such as symptomatic thirst, recurrent infections, and poor wound healing — and the harms of hypoglycaemia. A person-centred approach, with open discussion of targets with patients and carers, is central to both NICE NG28 and NHS England's frailty guidance.

Factors That Influence Individualised HbA1c Targets

Key factors include frailty status, cognitive function, renal impairment, choice of glucose-lowering agent, life expectancy, hypoglycaemia history, and patient preferences — all of which should be regularly reassessed.

Setting an appropriate HbA1c target for an older adult requires a thorough clinical assessment rather than a formulaic approach. Several key factors should be considered:

• Frailty status: Patients identified as moderately or severely frail using validated tools such as the Clinical Frailty Scale (CFS) or the Electronic Frailty Index (eFI) — commonly used in UK primary care — are at substantially higher risk of hypoglycaemia-related harm and generally warrant less stringent targets.

• Cognitive function: Dementia and cognitive impairment reduce a patient's ability to recognise hypoglycaemic symptoms, follow dietary advice, or self-manage medications safely.

• Comorbidities and polypharmacy: Conditions such as CKD, heart failure, and liver disease affect both the pharmacokinetics of glucose-lowering drugs and the risk of adverse events. CKD in particular alters the clearance of many agents, including metformin and certain sulphonylureas; NICE NG203 (Chronic Kidney Disease) and individual drug SmPCs (available via the MHRA's Electronic Medicines Compendium) provide relevant renal dosing guidance.

• Choice of glucose-lowering agent: Some drug classes — including DPP-4 inhibitors (gliptins), SGLT2 inhibitors, and GLP-1 receptor agonists — carry a low intrinsic risk of hypoglycaemia when used without insulin or a sulphonylurea, and may be preferable in older adults at high hypoglycaemia risk. Sulphonylureas and insulin carry a higher risk and require closer monitoring.

• Life expectancy: For patients with a limited prognosis — for example, those receiving palliative care — the priority shifts entirely towards symptom control and quality of life, and HbA1c monitoring may become less relevant.

• Hypoglycaemia history: A previous episode of severe hypoglycaemia is a strong indicator that current targets or medications need reassessment.

• Patient preferences and values: Shared decision-making is central to NICE guidance. Some patients prioritise avoiding injections or frequent monitoring; others are highly motivated to achieve tighter control.

These factors should be revisited regularly, as an individual's circumstances — and therefore their optimal target — can change significantly over time, particularly following a hospitalisation, a change in functional status, or the introduction of new medications.

Risks of Tight Glycaemic Control in Older People

Overly intensive glycaemic control in older adults risks hypoglycaemia, falls, fractures, cardiac arrhythmias, hospitalisation, and accelerated cognitive decline, particularly in those with pre-existing frailty or cardiovascular disease.

The risks associated with overly intensive glycaemic management in older adults are well-documented and should not be underestimated. The most immediate concern is hypoglycaemia, defined as a blood glucose level below 4.0 mmol/L. In older adults, hypoglycaemia can present atypically — with confusion, drowsiness, or behavioural change rather than the classic sweating and tremor — making it harder to identify and treat promptly.

The consequences of hypoglycaemia in this population are particularly serious:

• Falls and fractures: Hypoglycaemia impairs coordination and consciousness, significantly increasing fall risk. Hip fractures in older adults carry substantial morbidity and mortality.

• Cardiovascular events: Evidence from large trials, including ACCORD and ADVANCE, suggests that severe hypoglycaemia is associated with an increased risk of cardiac arrhythmias and acute coronary events, particularly in those with pre-existing cardiovascular disease. This evidence is observational and should be interpreted as an association rather than proven causation.

• Hospitalisation: Hypoglycaemic episodes are a common cause of diabetes-related emergency admissions in older adults in the UK.

• Cognitive decline: Recurrent hypoglycaemia has been linked to accelerated cognitive deterioration, creating a harmful cycle in patients already at risk of dementia.

If a person experiences severe hypoglycaemia — including loss of consciousness, a seizure, or no response to initial treatment — call 999 immediately. For less severe episodes, follow the NHS hypoglycaemia treatment guidance: consume a fast-acting carbohydrate (such as glucose tablets or a sugary drink), wait 15 minutes, and recheck blood glucose. The NHS website provides clear step-by-step advice on recognising and treating hypoglycaemia.

Beyond hypoglycaemia, tight control in frail patients may also lead to unintentional weight loss, reduced appetite, and a diminished quality of life — particularly if dietary restriction is pursued aggressively. The principle of 'first, do no harm' is especially pertinent here: the burden of treatment must always be weighed against its likely benefit in the individual patient.

Reviewing and Adjusting HbA1c Targets Over Time

NICE NG28 recommends HbA1c monitoring every 3–6 months and a formal annual review, with de-intensification actively considered when HbA1c is consistently below target or hypoglycaemic episodes occur.

Diabetes management in older adults is not static. In line with NICE NG28, HbA1c is typically measured every 3–6 months in people with type 2 diabetes, and approximately 3 months after any change in therapy to assess response. A formal review of targets and treatment regimens should take place at least annually in all patients, and more frequently in those whose clinical circumstances are changing.

For older adults, this review process is particularly important, as functional decline, new diagnoses, or changes in social support can rapidly alter the appropriateness of existing targets and medications. A structured annual review should include assessment of:

• Current HbA1c and whether it is within, above, or significantly below the agreed target

• Hypoglycaemia frequency and awareness

• Frailty and functional status (using tools such as the CFS or eFI)

• Renal function (eGFR and urine albumin-to-creatinine ratio), which affects drug safety

• Cardiovascular risk and any new comorbidities

• Medication burden and adherence

• Patient and carer understanding of the treatment plan

NICE advises that treatment intensification should generally be considered when HbA1c reaches 58 mmol/mol (7.5%) or above, subject to individual circumstances. Conversely, if a patient's HbA1c is consistently and significantly below their agreed target — particularly if they are on a sulphonylurea or insulin — or if hypoglycaemic episodes are occurring, de-intensification of treatment should be actively considered. This may involve reducing doses, switching to lower-risk agents, or simplifying regimens. De-intensification is a positive clinical intervention, not a sign of therapeutic failure, and should be framed as such in conversations with patients and families.

If HbA1c is persistently elevated and the patient is experiencing symptoms of hyperglycaemia such as thirst, polyuria, or recurrent infections, treatment escalation remains appropriate even in older age, provided it is done cautiously and with close monitoring.

When to Seek a Specialist Review or Medication Change

Specialist referral is warranted for recurrent hypoglycaemia, complex insulin regimens, significant renal impairment, or care home entry; call 999 immediately if a person loses consciousness or does not respond to hypoglycaemia treatment.

Most older adults with type 2 diabetes are managed effectively within primary care, but there are specific circumstances in which referral to a specialist diabetes team — or a prompt GP review — is warranted. Recognising these triggers is important for both patients and healthcare professionals.

Call 999 immediately if:

• A person with diabetes loses consciousness, has a seizure, or does not respond to hypoglycaemia treatment — this is a medical emergency.

Contact your GP or diabetes team promptly if:

• You or a family member has experienced a severe hypoglycaemic episode requiring assistance from another person

• Blood glucose levels are frequently low (below 4.0 mmol/L) even without obvious symptoms

• HbA1c has dropped unexpectedly or is well below the agreed target

• There has been a significant change in appetite, weight, or kidney function

• A new medication has been started that may interact with diabetes treatment

• There are concerns about the ability to self-manage safely at home

Referral to a specialist diabetes team or a frailty-focused diabetes service is particularly appropriate for patients with complex insulin regimens, recurrent hypoglycaemia, significant renal impairment, or those entering care homes. Many NHS trusts now offer dedicated diabetes and frailty clinics, and community diabetes specialist nurses can provide invaluable support in these situations.

Diabetes UK provides accessible resources on managing diabetes in older age, and the NHS website offers guidance on recognising and treating hypoglycaemia. Open communication with the GP or practice nurse remains the most important safeguard — no concern about blood glucose management is too small to raise.

Finally, if you or a healthcare professional suspects that a diabetes medicine has caused an unwanted side effect, this can be reported via the MHRA Yellow Card Scheme (available at yellowcard.mhra.gov.uk). Reporting helps to improve the safety of medicines for everyone.

Experiencing these side effects? Our pharmacists can help you navigate them →

Frequently Asked Questions